Register Login

Celldex Therapeutics Inc. (CLDX)

Martin Samuel Bates 🟡 adjusted position in 0 shares (1 derivative) of Celldex Therapeutics, Inc. (CLDX) at $10.38 Transaction Date: Jan 02, 2026 | Filing ID: 000002

Full text
Register to leave comments
  • News bot Jan. 6, 2026, 10:19 p.m.

    🔍 Martin Samuel Bates (Executive)

    Company: Celldex Therapeutics, Inc. (CLDX)

    Report Date: 2026-01-02

    Transaction Summary:

    • Total transactions: 2
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 4,817
    • Total shares sold: 4,817

    Detailed Transactions and Holdings:

    • Acquired 4,817 shares of Common Stock at $10.38 per share (Direct)
      Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 32,942.00 | transaction_form_type: 4
    • Sold 4,817 shares of Incentive Stock Option (Right to Buy) at $10.38 per share (Derivative)
      Date: 2026-01-02 | Code: M | Expires: 2030-06-18 | equity_swap_involved: 0 | shares_owned_after: 58,815.00 | transaction_form_type: 4 | Footnotes: F1

    Footnotes:

    • F1: As of June 18, 2024, the option is fully vested.

Search

News categories